EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
Sharma P, Farooki A, Fasching P, Loi S, Peterson K, Prat A, Tripathy D, Xu B, Yardley DA, Mills D, Klauss G, Wong C, Andre F (2020)
Publication Type: Conference contribution
Publication year: 2020
Journal
Publisher: ELSEVIER
City/Town: AMSTERDAM
Pages Range: S387-S388
Conference Proceedings Title: ANNALS OF ONCOLOGY
DOI: 10.1016/j.annonc.2020.08.451
Authors with CRIS profile
Involved external institutions
Institut Gustave-Roussy
France (FR)
Peter MacCallum Cancer Centre
Australia (AU)
Chinese Academy of Medical Sciences (CAMS)
China (CN)
Novartis AG
Switzerland (CH)
University of Kansas (KU)
United States (USA) (US)
Sarah Cannon Research Institute United Kingdom
United Kingdom (GB)
Universitat de Barcelona (UB) / University of Barcelona
Spain (ES)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
France (FR)
Peter MacCallum Cancer Centre
Australia (AU)
Chinese Academy of Medical Sciences (CAMS)
China (CN)
Novartis AG
Switzerland (CH)
University of Kansas (KU)
United States (USA) (US)
Sarah Cannon Research Institute United Kingdom
United Kingdom (GB)
Universitat de Barcelona (UB) / University of Barcelona
Spain (ES)
University of Texas MD Anderson Cancer Center
United States (USA) (US)
Memorial Sloan Kettering Cancer Center
United States (USA) (US)
How to cite
APA:
Sharma, P., Farooki, A., Fasching, P., Loi, S., Peterson, K., Prat, A.,... Andre, F. (2020). EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation. In ANNALS OF ONCOLOGY (pp. S387-S388). AMSTERDAM: ELSEVIER.
MLA:
Sharma, P., et al. "EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) plus nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation." Proceedings of the ESMO Virtual Congress AMSTERDAM: ELSEVIER, 2020. S387-S388.
BibTeX: Download